Surgical variables and risk factors associated with urinary leak following partial nephrectomy: Insights from a high-risk population.

M Milan Patel (HCA-USF Florida, Hudson, Florida, United States) L Lauren Loebach (National Institutes of Health, Bethesda, MD) R Ruben Blachman-Braun (National Institutes of Health, Bethesda, MD) B Braden Millan (Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD) J Jaskirat Saini (Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD) S Sandeep Gurram (Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD) W W Marston Linehan (National Cancer Institute, National Institutes of Health, Bethesda, MD) M Mark Wayne Ball (National Cancer Institute, National Institutes of Health, Bethesda, MD)

Abstract

604 Background: Urinary leak (UL) is a common complication following partial nephrectomy (PN). This study aims to identify the risk factors and surgical variables associated with the development of UL following PN in a cohort that includes a significant number of patients with hereditary renal cancer syndromes, multiple tumors, and a history of prior PNs. Methods: A retrospective chart review was conducted to identify patients who underwent PN at our institution from January 2006 to December 2023. Clinical, demographic, and surgical characteristics were recorded and analyzed. Statistical analysis was performed with SPSS v.29.0. Results: A total of 1173 PNs were analyzed, of which 89 (7.6%) had a UL. Patients had a median age at time of surgery of 50 [Interquartile range (IQR): 38 - 59] years, and 3 [IQR: 1 - 6] tumors removed per procedure. The robotic approach was utilized in 61.6% of cases, and the most common diagnosis was von Hippel-Lindau disease (47.4%). The frequency of UL was 5.1% for first-time PN, 10.4% for second, and 19.6% for third. Multivariable-adjusted analysis demonstrated an increased risk of UL with 3 rd PN (OR 2.379; p = 0.013), higher intraoperative estimated blood loss (per 100mL: OR 1.016; p = 0.006) and a decreased risk with robotic approach (OR 0.376; p < 0.001). (Table) Overall, 98.9% of UL cases (88 patients) were successfully managed with conservative management (post-op drain and foley), ureteral stent placement, percutaneous drain, or nephrostomy tube. Conclusions: In this cohort, UL is associated with the complexity of the surgery (repeat PN and higher EBL). A robotic approach had a lower risk of UL, while all but one UL were effectively managed non-operatively. Future research should investigate intraoperative and postoperative strategies to minimize this complication. Multivariable-adjusted logistic regression analysis evaluating the association between clinical variables and urinary leak after partial nephrectomy.* OR 95% CI p-value Partial nephrectomy count 1 1 2 1.693 0.973 - 2.944 0.062 3 2.379 1.200 - 4.714 0.013 ≥ 4 1.121 0.326 - 3.848 0.856 Surgical approach Open 1 Laparoscopic 0.324 0.042 - 2.517 0.281 Robotic 0.376 0.225 - 0.631 < 0.001 EBL (per 100 mL) 1.016 1.004 - 1.028 0.006 CI: Confidence interval, EBL: Estimated blood loss, OR: Odds ratio. *Analysis conducted using variables listed as well as age, gender, kidney laterality, race, ethnicity, presence of solitary kidney, surgical technique, total number of tumors removed, and size of largest tumor removed.

Article Details

Volume / Issue Vol. 43, Issue 5_suppl
Published February 10, 2025
Pages 604-604
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (8)

M

Milan Patel

HCA-USF Florida, Hudson, Florida, United States

L

Lauren Loebach

National Institutes of Health, Bethesda, MD

R

Ruben Blachman-Braun

National Institutes of Health, Bethesda, MD

B

Braden Millan

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

J

Jaskirat Saini

Urologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

S

Sandeep Gurram

Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

W

W Marston Linehan

National Cancer Institute, National Institutes of Health, Bethesda, MD

M

Mark Wayne Ball

National Cancer Institute, National Institutes of Health, Bethesda, MD